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Review
Investigating Cellular Recognition Using
CRISPR/Cas9 Genetic Screening
Zheng-Shan Chong ,1,2,* Gavin J. Wright,1 and Sumana Sharma1,3
Neighbouring cells can recognise and communicate with each other by direct
binding between cell surface receptor and ligand pairs. Examples of cellular rec-
ognition events include pathogen entry into a host cell, sperm–egg fusion, and
self/nonself discrimination by the immune system. Despite growing appreciation
of cell surface recognition molecules as potential therapeutic targets, identifying
key factors contributing to cellular recognition remains technically challenging to
perform on a genome-wide scale. Recently, genome-scale clustered regularly
interspaced short palindromic repeats (CRISPR) knockout or activation
(CRISPR-KO/CRISPRa) screens have been applied to identify the molecular de-
terminants of cellular recognition. In this review, we discuss how CRISPR-KO/
CRISPRa screening has contributed to our understanding of cellular recognition
processes, and how it can be applied to investigate these important interactions
in a range of biological contexts.
Cellular Recognition Is the First Step in Cell Signalling
Cells express a diverse set of signalling molecules on their surface to sense and respond to their
environment so that they respond appropriately as a function of their position within the organism.
Cellular recognition occurs when specific sets of plasma membrane receptors from different cells
bind to each other and trigger an intracellular signal that causes a change in cell state or behaviour
[1]. Cell surface molecules involved in cellular recognition are increasingly being regarded as at-
tractive therapeutic targets due to their role in initiating cellular responses and their accessibility
to systemically administered biologics such as monoclonal antibodies. For instance, immune
checkpoint molecules such as programmed cell death protein (PD)1, PD ligand (PDL)1, and cy-
totoxic T lymphocyte antigen (CTLA)4 have been the focus of recent cancer immunotherapy
aimed at blocking immune evasion by cancer cells. Antibodies against PD1, PDL1, and CTLA4
disrupt immunoinhibitory interactions and enable T-cells to recognise and kill cancer cells more
efficiently, resulting in tumour regression in some patients [2]. Cellular recognition is also particu-
larly important in infectious disease, as demonstrated by the development of C-C chemokine recep-
tor (CCR)5 inhibitors for antiretroviral therapy after CCR5 was identified as a coreceptor for human
immunodeficiency virus [3], and ongoing work targeting molecules like merozoite surface protein 1,
reticulocyte-binding protein homolog 5, and basigin (BSG), which are involved in erythrocyte recog-
nition and invasion by Plasmodium falciparum, a parasite that causes severe malaria [4,5].
Despite growing interest in targeting cellular recognition processes for therapy, the study of
molecular pathways contributing to cellular recognition remains challenging to perform at scale;
not least due to the difficulties of solubilising amphipathic plasma membrane proteins while
retaining low-affinity binding partners [6] (Box 1). This is in contrast to intracellular protein
complexes that tend to form stable complexes that are soluble in aqueous solutions, making
them more amenable to conventional high-throughput protein–protein interaction techniques
such as yeast-two-hybrid and affinity purification with mass spectrometry (AP-MS). As a result,
cell surface interactions are largely under-represented in most large-scale interaction datasets
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compiled using these techniques [6], although this may improve with recent advancements that
facilitate the isolation of plasma membrane-bound complexes using AP-MS [7].
Current Techniques for Cell Surface Interaction Screening
Several techniques have been developed or adapted specifically for the identification of cell sur-
face interactions [8]. In many cases, these approaches rely on the ability to express the
ectodomains of membrane-embedded receptors as soluble recombinant proteins that retain
their extracellular binding activity (Figure 1A). These techniques include expression cloning [9],
avidity-based extracellular interaction screening (AVEXIS) [10], protein microarrays [11], cDNA
overexpression microarrays [12], CRISPR-KO [13], and CRISPRa screening [14]. For CRISPR-
KO/CRISPRa screening, the soluble ectodomain of the ligand of interest is fused to a biotinylation
sequence that is clustered around a fluorescently conjugated streptavidin molecule. This serves
the dual purpose of enabling detection of the ligand of interest and increasing binding avidity to
facilitate the detection of low-affinity interactions. These protein complexes are then used in cel-
lular binding assays using fluorescence as a readout to indicate binding (Figure 1B). Where these
approaches diverge is how candidate receptors are screened, but since the different techniques
are beyond the scope of this review and have been extensively reviewed elsewhere [8,15], we
only focus on the last two techniques: CRISPR-KO and CRISPRa screening.
CRISPR-KO Screening
Since the discovery of CRISPR in bacteria, these systems have been widely adopted for various
applications such as genome-editing and large-scale screening for functional genetics and epige-
netics (Box 2). The CRISPR/Cas9 system has been particularly successful as it only requires one
nuclease (Cas9) and single guide RNA (sgRNA) to generate targeted gene knockouts (Figure 2A).
Given the current ease of generating complex oligomer libraries containing thousands of sgRNAs,
CRISPR/Cas9 technology has become the method of choice for genome-wide loss-of-function
screens and has been used to identify functional gene interaction networks underlying biological
Box 1. Affinity of Cell Surface Interactions versus Intracellular Protein Complexes
The affinity of an interaction is often indicated by its equilibrium dissociation constant (KD), with a higher KD value indicating
lower affinity since a higher concentration of ligand is needed to provide half-maximal occupancy at equilibrium. As an
example, the KD of nuclear-localised epigenetic factor tripartite motif-containing 28 (TRIM28) binding to Krüppel associated
box (KRAB) domains in zinc-finger proteins is 8 ± 2 nM [44]. By contrast, the KD of cell surface PD1–PDL1 and CD80-CTLA4
interactions are 8.2 ± 0.1and 0.26 ± 0.06 μM respectively, indicating lower affinities by 2–3 orders of magnitude [45,46].
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Figure 1. How Recombinant Bait Proteins Are Used for Cell Surface Receptor Identification in CRISPR/Cas9 Screens. (A) Cellular recognition is mediated
by receptor–ligand interactions at the cell surface. To identify the receptor for a ligand of interest, the soluble ectodomain of the ligand can be produced recombinantly as a
biotinylated bait protein and clustered around a tetrameric streptavidin molecule. (B) Cell binding assays use fluorescently labelled bait protein complexes to determine if a
population of cells express a receptor capable of binding the ligand. Binding can be measured by flow cytometry using fluorescence intensity as a readout.
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processes such as cell signalling and virus–host interaction [16–18]. CRISPR-KO screening now
provides an alternative genetic platform to systematically investigate genes that contribute to cel-
lular recognition on a genome-wide scale.
The procedure for performing cell surface receptor identification using genome-scale CRISPR-
KO screening has been described [19]. A typical screen begins with the identification of a
Cas9-expressing cell line that binds the ligand of interest (Figure 2B). Next, the cells are trans-
duced with a lentivirus library containing sgRNAs targeting all protein-coding genes in the ge-
nome at a low multiplicity of infection (MOI) of 0.3 to ensure that, on average, each cell receives
a single sgRNA. Due to the low MOI, not all cells are transduced, and untransduced cells must
be removed by fluorescence-activated cell sorting (FACS) or antibiotic selection, depending on
selection markers present in the lentiviral sgRNA expression vector. In this example, expression
of blue fluorescent protein (BFP) indicates successful lentiviral transduction and therefore
sgRNA expression (Figure 2B). Next, the transduced cell population is separated into control
and treatment populations of equal numbers. The control population is used to determine the
baseline frequency of each sgRNA within the population, which may vary between independent
transductions, while the treatment population undergoes further selection using a binding assay
as previously mentioned (Figure 1B). In this example, phycoerythrin (PE) fluorescence is used as a
readout for binding (Figure 2B). Transfected cells (BFP+) that have lost the ability to bind PE are
segregated from the bulk population using FACS and sent for next-generation sequencing to de-
termine the frequency of each sgRNA in the sorted population. The relative abundance of each
sgRNA is then compared between sorted and control populations to identify genetic factors es-
sential for binding of the protein ligand. The binding assay can be modified according to the spe-
cific aim of the screen; for instance, to study the determinants of receptor presentation on the
plasma membrane, monoclonal antibodies targeting a known receptor could be used instead
of a recombinant bait protein for sorting of the treatment population.
Box 2. How Do CRISPR/Cas9 Systems Work?
CRISPR genome editing systems are adaptive immunity strategies used by bacteria and archaea to provide protection
against foreign genetic elements. The simplest among the CRISPR systems is type II, which utilises a single large
multidomain effector protein (Cas9) guided by a coprocessed dual crRNA (CRISPR RNA): trans-activating crRNA
(tracrRNA) molecule to perform foreign DNA recognition and cleavage. The crRNA and tracrRNA duplex can be
substituted by an sgRN), a chimeric RNA performing the same function. The sgRNA can be engineered to target a DNA
sequence of choice by altering the 20 bps at the 5′ end complementary to the target DNA sequence.
Once at the target site, the two endonuclease domains of Cas9, the HNH and the RuvC domain, cleave the two strands of
DNA creating a double stranded break, which is repaired by the cellular DNA repair machinery either through nonhomol-
ogous end joining (NHEJ) pathway or the homology-dependent repair pathway. The NHEJ pathway, while being the pre-
ferred cellular pathway, is also error prone, which can lead to the generation of indel mutations leading to loss of gene
function.
CRISPRa systems are derived from the principles of conventional type II CRISPR systems; however, the Cas9 protein is
mutated such that it no longer cleaves DNA. This endonuclease dead Cas9 (dCas9) is fused to transcription activator do-
mains, creating a programmable transcriptional activator. Upon binding of dCas9 to a promoter, transcriptional activators
facilitate RNA polymerase recruitment to initiate transcription. A number of specific activation systems have been devel-
oped including the VP64-p65-Rta (VPR) system, the synergistic activation mediator (SAM) system, and the SunTag sys-
tem [47]. A similar principle is also used in the CRISPR interference system (CRISPRi). dCas9 bound to a DNA sequence
on its own creates steric hindrance to the transcriptional initiation or elongation machinery leading to transcriptional repres-
sion to an extent. Additional modifications to the dCas9 via fusing it to further transcriptional repressor protein domains
such as KRAB or KRAB and MeCP2 increases the efficiency of this repression [48].
Genome-wide CRISPR-based screens utilise libraries of sgRNA that are designed to target every gene in the genome. In
CRISPR-KO screens, Cas9 is targeted to the coding regions to create genome-wide knockout cell libraries, whereas in
CRISPRa systems, sgRNAs are targeted to the promoter regions to create libraries of overexpressed genes. Such libraries
provide a powerful platform to identify gene functions in an unbiased manner.
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Figure 2. Investigating theMolecular Determinants of Cellular Recognition Using CRISPR-KO/ CRISPRi andCRISPRaGenetic Screens. (A) Schematic of
how CRISPR-KO and CRISPRa systems work. Both systems are derived from Type II CRISPR/Cas systems from bacteria that are originally adaptive immunity strategies
to protect against foreign genetic elements (Box 2). CRISPR-KO uses the RNA-guided nuclease Cas9 to create double-stranded breaks in genomic DNA at specific
protein-coding loci as determined by a complementary guide sequence in the sgRNA. Errors in DNA repair of the double stranded break by nonhomologous end
joining in the cell subsequently lead to frameshift mutations and then disruption of the target gene. By contrast, CRISPRa uses an RNA-guided but nuclease-inactive
dCas9 fused to transcriptional activator domains to recruit transcription factors and RNA polymerase to the promoter regions of target genes to increase gene
expression. (B) Diagram showing how CRISPR-KO/i and CRISPRa screens are conducted. CRISPRi utilises a catalytically inactive dCas9 protein to inhibit transcription
and suppress gene expression (Box 2). A population of mutagenised cells are generated by transducing the relevant cell lines with a lentiviral sgRNA library and
separating into treatment and control populations. The treatment population undergoes a cell binding assay and FACS to segregate cells that have either lost or gained
(Figure legend continued at the bottom of the next page.)
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CRISPRa Screening
Rapid adoption of CRISPR/Cas9 technologies has driven the development of Cas9 variants de-
signed to increase gene expression rather than disrupt or repress it (CRISPRa; Box 2). CRISPRa
utilises a nuclease-inactive Cas9 fused to one or more transcriptional activator domains, which
can be recruited to the promoter regions of target genes using an appropriate sgRNA (Figure
2A). The workflow for conducting CRISPRa screens is similar to that for CRISPR-KO screens,
with a few keymodifications such as the use of cell lines expressing ‘dead’Cas9 (dCas9) activators
(Figure 2B). Unlike CRISPR-KO screens, the cell line used for screening does not have to be able to
bind to the protein of interest initially. Cells are also transduced with a CRISPRa lentiviral sgRNA li-
brary that contains sgRNAs targeting the promoter rather than coding regions of genes. For iden-
tifying cell surface interactions, focused CRISPRa libraries that only target genes encoding
membrane proteins are available [14,20], although it is also possible to use genome-wide libraries
[14,20]. Binding assays are conducted as previously described (Figure 1B) to detect transduced
cells (BFP+) that have acquired the ability to bind to a PE-labelled bait protein of interest (PE+),
and this population is isolated using FACS for sequencing and subsequent analysis. Formore com-
prehensive details on conducting CRISPR-KO and CRISPRa screens in general, including tips for
experimental design, normalisation, and statistical analysis, we refer the reader to the protocol
paper by Joung et al. [21].
Contribution of CRISPR-KO/CRISPRa Screening to Our Understanding of
Cellular Recognition
CRISPR-KO Screens Identify Factors That Directly and Indirectly Affect Binding
A cellular recognition event between two cells involvesmore than just the expression of the recep-
tor and ligand in question. Binding also depends on receptor presentation at the cell surface,
which may in turn rely on the presence of specific post-translational modifications (PTMs) and
chaperone proteins. Unlike many other existing methods to study cellular recognition that only
screen for directly interacting receptor–ligand pairs, genome-scale CRISPR-KO screens have
the potential to reveal all genes that are required for correct display of the receptor in the plasma
membrane. For instance, CRISPR-KO screening was used to identify CKLF-like MARVEL trans-
membrane domain containing 6 (CMTM6) as a master regulator of immune checkpoint inhibitor
PDL1 expression on the plasma membrane [22,23], and solute carrier family 16 member 1
(SLC16A1) as a chaperone for expression of BSG, an erythrocyte receptor for P. falciparum [13].
Other CRISPR-KO studies also identified important PTMs such as glycosylphosphatidylinositol an-
chors and N-linked glycosylation required for cell surface localisation of innate immune receptors
CD59 and galectin-3, respectively [13,24].
PTMs such as glycosylation, sulfation, and sialylation, can also act as coreceptors or modify bind-
ing properties directly. CRISPR-KO screens now present the possibility of detecting PTMs that
are important for binding, and several such studies have identified heparan sulfate (HS), a poly-
saccharide modification commonly found on plasma membrane proteins, as a common
coreceptor mostly in the context of host–pathogen interactions [13,25–27]. The same studies ob-
served that HS binding was additive rather than codependent on other receptors, indicating that
HS acts to enhance binding, while in some cases ligand binding was completely abolished in cells
which are unable to form sulfated heparan moieties, suggesting that HS can also act as a recep-
tor and mediate binding independently of a specific protein. CRISPR-KO screens have also
the ability to bind to the ligand of interest for CRISPR-KO/i or CRISPRa screens, respectively. Factors mediating binding are then determined by deep sequencing and
comparison of sgRNA abundance in the sorted population to that in the control population. Abbreviations: BFP, blue fluorescent protein; CRISPR, clustered regularly
interspaced short palindromic repeats; CRISPRa, CRISPR activation; CRISPRi, CRISPR inhibition; CRISPR-KO, CRISPR knockout; dCas9, dead Cas9; FACS,
fluorescence-activated cell sorting; MOI, multiplicity of infection; NGS, next-generation sequencing PE, phycoerythrin; sgRNA, single guide RNA.
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identified host factors involved in viral entry of murine norovirus, dengue virus, and hepatitis C
virus, among others [16,28,29].
Limitations of CRISPR-KO Screening
While powerful, there are a few limitations of using CRISPR-KO screens to study cellular
recognition. The main conceptual limitation of CRISPR-KO screening is that genes that are either
essential for cell viability or functionally redundant are not identified. The longer the mutant cell
library is kept in culture, the greater the chance that cells containing sgRNAs targeting genes
essential for proliferation are depleted. However, essential genes contributing to cell surface rec-
ognitionmay be identified by performing phenotypic selection at an earlier time point after lentiviral
transduction. Another limitation of the CRISPR-KO screen is the need to identify a cell line that
binds to the protein of interest prior to screening. This often requires prescreening a large number
of cell lines, which can be time consuming. Due to the high number of cell surface proteins that
display HS-binding properties, we also recommend prescreening ligands for HS binding by com-
paring binding with an isogenic line harbouring a knockout in either SLC35B2 or EXTL3, which
are key enzymes required for HS biosynthesis [13].
CRISPRa Screens Simultaneously Detect Multiple Binding Partners
Some of the shortcomings of CRISPR-KO screening can be addressed using the complementary
CRISPRa approach. For instance, CRISPRa screens do not require extensive prescreening to
identify a cell line that binds to the protein of interest, and CRISPRa libraries do not show de-
pletion of sgRNA targeting genes detrimental to proliferation after extended periods in culture
[14]. One of the advantages of CRISPRa screening over CRISPR-KO is the ability to detect
multiple receptors in a single experiment, as was the case for the identification of interactions
between neuronal receptor adhesion G-coupled receptor B1 (ADGRB1) and all three members
of the reticulon-4 receptor (RTN4R) family [14]. In addition, CRISPRa screening has been ap-
plied to identify host cell factors such as N-acetylgalactosaminyltransferase 2 (B4GALNT2)
and interferons that protect against viral infection by multiple subtypes of Influenza A virus
and Zika viruses [30,31].
Limitations of CRISPRa Screening
By contrast to the CRISPR-KO approach which can reveal all nonessential, nonredundant
genes required for the cell surface display of a receptor, CRISPRa screening is more suited
to determine the gene encoding the directly interacting receptors themselves. Nonetheless,
we have observed that CRISPRa screening of HS-binding proteins tends to identify syndecan
(SDC)1 and 2 as binding partners, as they are HS proteoglycans [14]. The study that identified
glycosyltransferase B4GALNT2 as a factor that prevented host-cell invasion by influenza A
viruses through modifications of α2,3-linked sialic acid containing glycans [35] also indicated
that CRISPRa screens can still be useful for detecting some forms of glycan involvement in
cellular recognition.
CRISPR activation screens can also be limited by the receptors that can be expressed on the sur-
face of the cells in a correctly folded form as transcriptional activation of a single genemight not be
sufficient to achieve cell surface expression for proteins that rely on additional cellular accessory
factors such as transporters and chaperones. For instance, while attempting to overexpress pro-
teins that are restricted to erythroid cells such as rhesus factor antigen (Rh)D and SLC4A1 in
immortalised HEK293 cells using the CRISPRa system, we observed that while we were able
to achieve over 1000-fold overexpression at the mRNA level, this did not correspond to increases
in protein expression at the cell surface [14]. One likely explanation is that HEK293 cells do not
express accessory factors such as RhAG and glycophorin A, which are required for cell surface
Trends in Cell Biology
624 Trends in Cell Biology, August 2020, Vol. 30, No. 8
localisation of RhD and SLC4A1, respectively [32,33]. Conducting screens in a more biologically
relevant cell line such as immortalised erythroid lines might overcome this problem.
Functional Studies Complement Results from CRISPR/Cas9 Screens
Analysis of CRISPR/Cas9 screen data generates a ranked list of genes based on the likeli-
hood that sgRNAs targeting that gene are enriched in the sorted treatment population as
compared with the control population. In our experience, the results of CRISPR-KO and
CRISPRa cell surface interaction screens are reproducible, with near complete overlap of
top-ranked genes between replicates. As such, two replicates are generally sufficient for
identifying receptors or key pathways involved in binding. However, the reader should be
mindful that such screens are typically conducted on immortalised cell lines such as
HEK293 cells that are easy to grow and manipulate, and that CRISPR-KO/CRISPRa screen-
ing may suffer from artefacts caused by off-target binding of Cas9 or ectopic overexpression
of target proteins that have been previously demonstrated in cancer cell lines and yeast
[34–36], although this has so far not been studied in cellular recognition screens. It is there-
fore crucial to validate the physiological relevance of any interactions found by CRISPR/Cas9
screens in more functionally relevant models. For instance, we recently identified HS as the
binding partner of platelet inhibitory protein G6b using a CRISPR-KO screen, and subse-
quent in vitro and in vivo experiments in mice revealed that G6b-B when bound to multivalent
HS side chains induces downstream signalling in platelets via tyrosine phosphatases Shp1
and Shp2 [37].
Concluding Remarks
On balance, CRISPR-KO and CRISPRa screens are robust and powerful tools for systemati-
cally investigating the molecular determinants of cellular recognition at a genome-wide scale
(Figure 3, Key Figure). These approaches can go beyond identifying novel cell surface recep-
tor–ligand pairs to detecting PTMs and chaperones that indirectly affect binding, as well as
highlighting the role of glycans such as HS in cellular recognition. Nonetheless, a number of
questions remain to be answered (see Outstanding Questions), a key one being: how well do
the results from CRISPR/Cas9 screens in immortalised cell lines reflect what goes on in a phys-
iological context in vivo? This is not as straightforward as it sounds, and while some studies
have successfully demonstrated the relevance of interactions identified using CRISPR-KO/
CRISPRa screening in mice models or explant cultures [31,37], others have struggled to find
a suitable in vivo assay for validation.
Multiple CRISPR-KO screening studies have identified a number of HS-binding proteins,
highlighting the importance of HS in cellular recognition. While HS has been known to play mul-
tiple roles in viral attachment, immune activation, and development [38], it is unclear how these
interactions are independently regulated in the body and how specificity is achieved. To this
end, CRISPR/Cas9 techniques could be applied to help delineate the differences between HS
molecules displayed on the surface of different cell types and how that might affect cellular recog-
nition. Using fluorescently labelled glycans [39], CRISPRa screening could also be used to gen-
erate a comprehensive list of HS-binding cell surface proteins, and compare it with that of
other glycans such as chondroitin sulfate (Figure 3).
One aspect of cellular recognition that CRISPR/Cas9 screening does not currently address is
how plasma membrane dynamics and receptor density affect ligand binding. For instance, active
and inactive integrins have been shown to form nanoclusters with different spatial organisations
[40]. CRISPR/Cas9 techniques are not suitable for such studies, but a generic cell surface ligand
system has recently been developed to address this question [41].
Outstanding Questions
How can binding of a recombinant
protein to the surface of immortalised
cell lines be interpreted in a biological
context.
What is the role of HS molecules
displayed on the surface of multiple
cell types in cell recognition events
in vivo?
What role do receptor density and
plasma membrane dynamics play in
cellular recognition?
How can cellular recognition screens
be performed in primary cells?
Can CRISPR/Cas9 screening be
adapted to identify binding mediated
by molecules that are poorly studied,
for example glycolipids and exosomes?
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Despite its limitations, we believe that CRISPR/Cas9 screening has potential for furthering our un-
derstanding of cellular recognition. CRISPR/Cas9 screens have already been performed in pri-
mary T cells [42], which could improve translatability of findings, while improvements in the
synthesis and purification of glycolipids and exosomes could make them amenable for
CRISPR/Cas9 screening to better understand their role in cell–cell communication in the near fu-
ture (Figure 3). Exosomes represent an emerging class of therapeutics for a broad range of dis-
eases, but the mechanisms by which they recognise and bind to target cells is still poorly
characterised [43]. We therefore envision that CRISPR/Cas9 screeningwill continue to be a useful
technique in the field of cellular recognition.
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